# Ted Belleza

> Ted Belleza is the founder, President and CEO of URO-1, Inc., a medical device company based in Greensboro, North Carolina that develops the SUREcore biopsy needle and coreCARE specimen-retrieval kit for prostate and soft tissue biopsy. A serial MedTech entrepreneur with more than 35 years of business experience and prior roles at Gynesonics (acquired by Hologic), Endosee (acquired by CooperSurgical) and LiveLeaf Bioscience, Belleza came out of retirement after his own prostate cancer experience to redesign what he calls an antiquated biopsy procedure, aiming to give physicians bigger, better and more consistent tissue samples.

- **Role:** Founder, President & CEO at URO-1, Inc.
- **Organizations:** URO-1, Inc., Ted Belleza Consulting, Endosee Corp. (acquired by CooperSurgical / Cooper Companies), LiveLeaf Bioscience, Gynesonics, Inc. (acquired by Hologic)
- **Nationality:** American
- **Known for:** Founded URO-1, Inc. and led it from concept to FDA-cleared products, Secured U.S. Patent #11,903,569 for the SUREcore soft tissue biopsy needle, Achieved FDA clearance for the SUREcore biopsy needle and coreCARE specimen-retrieval kit

## Career timeline

- **2007-2009** — Vice President of Clinical Marketing at Gynesonics, Inc. (later acquired by Hologic)
- **2009-2012** — Chief Commercial Officer at LiveLeaf Bioscience
- **2010-2014** — Co-Founder and VP Business Development at Endosee Corp. (later acquired by CooperSurgical)
- **2017** — Founded and became CEO of URO-1, Inc., launched in Winston-Salem, North Carolina
- **2022** — URO-1 reached its $5.0M Series A goal and announced FDA clearance of SUREcore and coreCARE
- **2024** — URO-1 awarded U.S. Patent #11,903,569 for the SUREcore soft tissue biopsy needle

## Achievements

- Founded URO-1, Inc. and led it from concept to FDA-cleared products
- Secured U.S. Patent #11,903,569 for the SUREcore soft tissue biopsy needle
- Achieved FDA clearance for the SUREcore biopsy needle and coreCARE specimen-retrieval kit
- Raised a $5.0M Series A round led by Acorn Campus of Taiwan
- Clinical studies showed SUREcore delivered 12-21% greater tissue volume by weight versus standard needles
- Co-founded Endosee Corp., later acquired by CooperSurgical
- Held VP roles at Gynesonics, later acquired by Hologic

## Latest updates

- **2024-03** — URO-1 raised a Series A round (latest funding $8.0M reported), part of $10.6M total funding
- **2024-02** — URO-1 awarded U.S. Patent #11,903,569 for the SUREcore soft tissue biopsy needle

## Links

- Website: https://uro1medical.com
- LinkedIn: http://www.linkedin.com/in/ted-belleza-18337911

---

Profile page: https://yespress.io/ted-belleza
Published by YesPress — https://yespress.io
Last updated: 2026-07-24